Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash from Operations (2021 - 2025)

Historic Cash from Operations for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $77.5 million.

  • Krystal Biotech's Cash from Operations rose 4667.6% to $77.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $200.9 million, marking a year-over-year increase of 6274.91%. This contributed to the annual value of $200.9 million for FY2025, which is 6274.91% up from last year.
  • Per Krystal Biotech's latest filing, its Cash from Operations stood at $77.5 million for Q4 2025, which was up 4667.6% from $39.7 million recorded in Q3 2025.
  • Krystal Biotech's Cash from Operations' 5-year high stood at $77.5 million during Q4 2025, with a 5-year trough of -$43.1 million in Q2 2022.
  • Moreover, its 5-year median value for Cash from Operations was -$8.5 million (2021), whereas its average is $4.3 million.
  • In the last 5 years, Krystal Biotech's Cash from Operations crashed by 32510.61% in 2022 and then soared by 136509.12% in 2025.
  • Over the past 5 years, Krystal Biotech's Cash from Operations (Quarter) stood at -$20.9 million in 2021, then dropped by 6.84% to -$22.3 million in 2022, then surged by 67.61% to -$7.2 million in 2023, then soared by 830.68% to $52.8 million in 2024, then soared by 46.68% to $77.5 million in 2025.
  • Its Cash from Operations stands at $77.5 million for Q4 2025, versus $39.7 million for Q3 2025 and $52.7 million for Q2 2025.